Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks - PubMed (original) (raw)
Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks
Kun-Hsing Yu et al. BMC Med. 2020.
Abstract
Background: Ovarian cancer causes 151,900 deaths per year worldwide. Treatment and prognosis are primarily determined by the histopathologic interpretation in combination with molecular diagnosis. However, the relationship between histopathology patterns and molecular alterations is not fully understood, and it is difficult to predict patients' chemotherapy response using the known clinical and histological variables.
Methods: We analyzed the whole-slide histopathology images, RNA-Seq, and proteomics data from 587 primary serous ovarian adenocarcinoma patients and developed a systematic algorithm to integrate histopathology and functional omics findings and to predict patients' response to platinum-based chemotherapy.
Results: Our convolutional neural networks identified the cancerous regions with areas under the receiver operating characteristic curve (AUCs) > 0.95 and classified tumor grade with AUCs > 0.80. Functional omics analysis revealed that expression levels of proteins participated in innate immune responses and catabolic pathways are associated with tumor grade. Quantitative histopathology analysis successfully stratified patients with different response to platinum-based chemotherapy (P = 0.003).
Conclusions: These results indicated the potential clinical utility of quantitative histopathology evaluation in tumor cell detection and chemotherapy response prediction. The developed algorithm is easily extensible to other tumor types and treatment modalities.
Keywords: Digital pathology; Gene expression; Machine learning; Platinum response; Proteomics; Serous ovarian carcinoma.
Conflict of interest statement
To maximize the impact of this study, Harvard Medical School submitted a non-provisional patent application to the United States Patent and Trademark Office (USPTO).
Figures
Fig. 1
Integrative histopathology-functional omics analyses on serous ovarian carcinoma. a A model of the informatics workflow in this study. b Convolutional neural networks identified regions with tumor cells of serous ovarian carcinoma. Receiver operating characteristic (ROC) curves of convolutional neural networks that classified regions with tumor cells from those without tumor cells in the independent test set are shown. Areas under the receiver operating characteristic curves (AUCs) in the independent test set: AlexNet = 0.955 ± 0.010; GoogLeNet = 0.974 ± 0.004; VGGNet = 0.975 ± 0.001. c Gradient-weighted class activation maps (grad-CAMs) confirmed that the CNN models focused on the cancerous part of the histopathology slides when classifying malignant tissues from benign ones. The original hematoxylin-and-eosin-stained histopathology image was also shown
Fig. 2
Quantitative histopathology analysis identified tumor grade. a ROC curves of convolutional neural networks that classified the pathology grade of serous ovarian carcinoma. The sensitivity and specificity for identifying high-grade serous ovarian carcinoma are shown. AUC in the independent test set: AlexNet = 0.760 ± 0.082; GoogLeNet = 0.810 ± 0.067; VGGNet = 0.812 ± 0.088. b The gradient-weighted class activation map (grad-CAM) of a histopathology image of a low-grade ovarian cancer patient and the original hematoxylin-and-eosin-stained histopathology image. Tumor cells and differentiated cellular structures received higher weighted in the grad-CAM. c The grad-CAM of a histopathology image of a high-grade ovarian cancer patient and the original hematoxylin-and-eosin-stained histopathology image. Clusters of tumor cells with poor differentiation were highlighted by the grad-CAM
Fig. 3
Proteomics analyses revealed the molecular profiles associated with tumor grade. a The expression levels of 32 proteins are associated with tumor grade. Sidebar: red indicates high-grade tumors; blue indicates low-to-moderate-grade tumors. b The protein-protein interaction (PPI) network of the proteins associated with tumor grade. These 32 proteins have significantly enriched PPIs (P < 6.66 × 10−16). The color of the edges shows the information source of the curated protein-protein interactions in the STRING database
Fig. 4
Convolutional neural networks predicted the platinum-based chemotherapy response of patients with serous ovarian carcinoma. a Convolutional neural networks stratified serous ovarian carcinoma patients with different platinum-based chemotherapy response (log-rank test P = 0.003). Kaplan-Meier curves of the image-based stratification in the test cases are shown. b The gradient-weighted class activation map (grad-CAM) of a histopathology image of a serous ovarian carcinoma patient with short platinum-free interval (PFI) and the original hematoxylin-and-eosin-stained histopathology image. c The grad-CAM of a histopathology image of a serous ovarian carcinoma patient with long PFI and the original hematoxylin-and-eosin-stained histopathology image. Grad-CAMs highlighted regions occupied by the tumor cells
Fig. 5
Proteomic profiles are associated with platinum-based chemotherapy response. a 72 proteins are significantly associated with the platinum-free interval (PFI) of serous ovarian cancer patients. b The interaction network of the proteins associated with PFI. Proteins associated with platinum response have significantly enriched protein-protein interactions (P = 7.86 × 10−9). The color of the edges shows the information source of the curated protein-protein interactions in the STRING database
Similar articles
- Predicting Ovarian Cancer Patients' Clinical Response to Platinum-Based Chemotherapy by Their Tumor Proteomic Signatures.
Yu KH, Levine DA, Zhang H, Chan DW, Zhang Z, Snyder M. Yu KH, et al. J Proteome Res. 2016 Aug 5;15(8):2455-65. doi: 10.1021/acs.jproteome.5b01129. Epub 2016 Jul 8. J Proteome Res. 2016. PMID: 27312948 Free PMC article. - Prediction of Ovarian Cancer Response to Therapy Based on Deep Learning Analysis of Histopathology Images.
Liu Y, Lawson BC, Huang X, Broom BM, Weinstein JN. Liu Y, et al. Cancers (Basel). 2023 Aug 10;15(16):4044. doi: 10.3390/cancers15164044. Cancers (Basel). 2023. PMID: 37627071 Free PMC article. Retracted. - Platinum-based chemotherapy for advanced-stage serous ovarian carcinoma of low malignant potential.
Barakat RR, Benjamin I, Lewis JL Jr, Saigo PE, Curtin JP, Hoskins WJ. Barakat RR, et al. Gynecol Oncol. 1995 Dec;59(3):390-3. doi: 10.1006/gyno.1995.9956. Gynecol Oncol. 1995. PMID: 8522261 - Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment.
van Zyl B, Tang D, Bowden NA. van Zyl B, et al. Endocr Relat Cancer. 2018 May;25(5):R303-R318. doi: 10.1530/ERC-17-0336. Epub 2018 Feb 27. Endocr Relat Cancer. 2018. PMID: 29487129 Review. - Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
Alkema NG, Wisman GB, van der Zee AG, van Vugt MA, de Jong S. Alkema NG, et al. Drug Resist Updat. 2016 Jan;24:55-69. doi: 10.1016/j.drup.2015.11.005. Epub 2015 Nov 26. Drug Resist Updat. 2016. PMID: 26830315 Review.
Cited by
- A pathology foundation model for cancer diagnosis and prognosis prediction.
Wang X, Zhao J, Marostica E, Yuan W, Jin J, Zhang J, Li R, Tang H, Wang K, Li Y, Wang F, Peng Y, Zhu J, Zhang J, Jackson CR, Zhang J, Dillon D, Lin NU, Sholl L, Denize T, Meredith D, Ligon KL, Signoretti S, Ogino S, Golden JA, Nasrallah MP, Han X, Yang S, Yu KH. Wang X, et al. Nature. 2024 Sep 4. doi: 10.1038/s41586-024-07894-z. Online ahead of print. Nature. 2024. PMID: 39232164 - Histopathologic image-based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer.
Ahn B, Moon D, Kim HS, Lee C, Cho NH, Choi HK, Kim D, Lee JY, Nam EJ, Won D, An HJ, Kwon SY, Shin SJ, Jung HR, Kwon D, Park H, Kim M, Cha YJ, Park H, Lee Y, Noh S, Lee YM, Choi SE, Kim JM, Sung SH, Park E. Ahn B, et al. Nat Commun. 2024 May 18;15(1):4253. doi: 10.1038/s41467-024-48667-6. Nat Commun. 2024. PMID: 38762636 Free PMC article. - Artificial intelligence in digital pathology: a systematic review and meta-analysis of diagnostic test accuracy.
McGenity C, Clarke EL, Jennings C, Matthews G, Cartlidge C, Freduah-Agyemang H, Stocken DD, Treanor D. McGenity C, et al. NPJ Digit Med. 2024 May 4;7(1):114. doi: 10.1038/s41746-024-01106-8. NPJ Digit Med. 2024. PMID: 38704465 Free PMC article. Review. - Predictive Value of Machine Learning for Platinum Chemotherapy Responses in Ovarian Cancer: Systematic Review and Meta-Analysis.
Wang Q, Chang Z, Liu X, Wang Y, Feng C, Ping Y, Feng X. Wang Q, et al. J Med Internet Res. 2024 Jan 22;26:e48527. doi: 10.2196/48527. J Med Internet Res. 2024. PMID: 38252469 Free PMC article. Review. - Role of epithelial-mesenchymal transition factor SNAI1 and its targets in ovarian cancer aggressiveness.
Suzuki T, Conant A, Curow C, Alexander A, Ioffe Y, Unternaehrer JJ. Suzuki T, et al. J Cancer Metastasis Treat. 2023;9:25. doi: 10.20517/2394-4722.2023.34. Epub 2023 Jun 30. J Cancer Metastasis Treat. 2023. PMID: 38009093 Free PMC article.
References
- Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol. 1994;10(1):31–46. doi: 10.1002/ssu.2980100107. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical